Treating Immune-Mediated, Inflammatory Diseases with Janus Kinase (JAK) Inhibitors
| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant |
| Target Specialties: | Rheumatology |
| Credits Available: | 4.75 AMA PRA Category 1 Credits™ |
Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, can prove challenging to address in real-world settings. Although biologics directed against TNF-α can rapidly and sustainably induce clinical remission of these conditions, they have incomplete efficacy; many other conventional treatments used alongside biologics additionally have complex safety profiles that limit their use. These limitations have spurred the development and examination of novel agents, such as Janus Kinase (JAK) inhibitors, in patients with inadequately controlled disease. Through this three-part, small-group educational program, rheumatologists and other supporting healthcare providers can gain greater familiarity with the mechanisms of action behind different JAK inhibitors, evaluate their efficacy and safety in different patient populations, and become acquainted with strategies to improve access to these agents on behalf of their patients. In doing so, clinicians can ensure that the next generation of therapies for immune-mediated inflammatory diseases are used to their fullest potential.
CME/CE Accreditation Information
Itinerary
Part 1
Answer the following questions to assess your knowledge of JAK inhibitors as they are used to treat patients with immune-mediated, inflammatory diseases.
This first self-study module is designed to enhance your understanding of Janus kinase (JAK) inhibition.
This second self-study module is designed to increase your familiarity with late-stage clinical trial data for Janus kinase inhibitors.
Identify and familiarize yourself with strategies to limit the frequency of adverse events tied to JAK inhibitors and improve access to JAK inhibitors for patients with rheumatic diseases.
Answer the following questions to assess your knowledge on the use of JAK inhibitors to treat patients with immune-mediated, inflammatory diseases.
This live group discussion focuses on the educational content of the self-study modules that examined the mechanisms of action for JAK inhibitors, efficacy and safety data of JAK inhibitors in patients with immune-mediated, inflammatory diseases, and strategies to improve JAK inhibitor access.
Part 2
This activity features a 40-year-old female who presents with symptoms of uncontrolled RA. This patient activity focuses on clinical considerations in the treatment-refractory setting.
This activity features a 60-year-old male who presents with symptoms of uncontrolled PsA while having multiple medical comorbidities. It focuses on balancing risks and benefits with therapy in treatment-refractory settings.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients who are eligible for treatment with JAK inhibitors.
This live group discussion is focused on the case studies found in the Group Challenges, which explore how to best use JAK inhibitors in the treatment of patients with immune-mediated, inflammatory diseases.
Interested in becoming a Group Leader?
Ideal Group Leaders should be Rheumatologists, and Rheumatology Advanced Practice Providers. Apply Now
Interested in participating in this curriculum? You can join one of the following groups:
Completed Groups
Ibtissam Gad, MDAssistant Professor
